Comprehensive Approaches to Prevent and Manage Urinary Tract Infections (UTIs) in Residents: Asymptomatic Bacteriuria



Quality Innovation Network -Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES iQUALITY IMPROVEMENT & INNOVATION GROUP

Bite-sized Learning

Objectives

- Discuss the prevalence of asymptomatic bacteriuria (ASB) in long-term care population
- Review the clinical implications of ASB
- Describe urine culture stewardship and its relationship to the management of ASB
- Share Alliant Health Solutions quality improvement resources to support UTI prevention initiatives.



Urine Culture Stewardship

- A multifaceted approach to ensure that urine cultures are:
 - Performed only when appropriate indications are present in order to determine if treatment with antibiotics is indicated

AND

- Collected, stored, and processed in a manner to best prevent contamination with microorganisms such as bacteria
- Essential strategy to prevent misdiagnosis of urinary tract infections and reduce unnecessary testing and inappropriate antibiotic use

Preventing CAUTI: Focus on Culturing Stewardship. Content last reviewed May 2023. Agency for Healthcare Research and Quality, Rockville, MD. <u>https://www.ahrq.gov/hai/cauti-tools/phys-championsgd/section7.html</u>





Asymptomatic Bacteriuria (ASB)

- Presence of one or more species of bacteria growing in the urine at specified quantitative counts (≥10⁵ colony-forming units [CFU]/mL or ≥10⁸ CFU/L), irrespective of the presence of pyuria, in the absence of signs or symptoms attributable to urinary tract infection (UTI) (e.g., dysuria, frequency, urgency, fever, flank pain)
- Positive urine culture in a patient with no signs or symptoms of a urinary tract infection, often associated with pyuria (urine containing ≥10 white blood cells per high-powered field)

Population	Prevalence of ASB	Prevalence of Pyuria in Persons With ASB
Healthy premenopausal women	1–5%	32%
Women 70–90 years old	11–16%	
Female long-term care residents	25–50%	90%
Male long-term care residents	15–50%	90%
Women with diabetes	9–27%	70%
Men with diabetes	1–11%	
People receiving hemodialysis	25%	90%
Presence of indwelling urinary catheter	> 90%	50–100%

https://www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/best-practices/ASB-one-page.pdf



Asymptomatic Bacteriuria (ASB)

- The majority of patients/residents with ASB and/or asymptomatic pyuria **SHOULD NOT** be treated.
- Studies have demonstrated that treatment of ASB does not prevent UTIs.
 - Treatment associated with adverse events related to antibiotic use and the development of future UTIs that are antibiotic resistant.
- Exceptions
 - Pregnant patients: treatment prevents preterm labor and pyelonephritis.
 - Patients about to undergo a urologic procedure in which mucosal bleeding is expected (not urinary catheter placement): treatment prevents urosepsis.

TABLE 1 Screening for Asymptomatic Bacteriuria in Adults: Clinical Summary of the USPSTF Recommendation Population This applies to adults 18 years and older and pregnant persons of any age without signs and symptoms of a urinary tract infection. It does not apply to persons who have chronic medical or urinary tract conditions or are hospitalized or living in institutions such as nursing homes. Recommendation For pregnant persons: Grade B For nonpregnant adults: Grade D

Recommendation	For pregnant persons: Grade B Screen persons who are pregnant for asymptomatic bacteriuria with a urine culture.	For nonpregnant adults: Grade D Do not screen adults who are not pregnant for asymptomatic bacteriuria.	
What's new?	This recommendation is consistent with the 2008 USPSTF recommendation. The USPSTF continues to recommend screening for pregnant persons and recommends against screening for nonpregnant adults.		
How to imple- ment this recommendation?	Screen. Screen pregnant persons for asymptomatic bacteriuria using a mid- stream, clean-catch urine culture at the first prenatal visit or at 12 to 16 weeks of gestation, whichever is earlier. A urine culture showing >100,000 CFU/mL of a single uropathogen or >10,000 CFU/mL if the pathogen is group B streptococcus indicates treatment.		
Where to read the full recommenda- tion statement?	Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation, including benefits and harms; supporting evidence; and recommendations of others.		

Note: For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, go to https://www.uspreventiveservicestaskforce.org/.


CFU = colony-forming units; USPSTF = U.S. Preventive Services Task Force.



How Can I Prevent Unnecessary Treatment of ASB?

- Do not order urine cultures unless your resident has signs and symptoms of a UTI
- Establish urine culture protocols

 Document appropriate indications
 - Urine culture collection protocol
 - Urine culture collection competency
- Develop tools in the electronic health record to prompt providers to document indications for sending a urine culture
- Work with the lab to determine from where and why urine cultures are being sent to identify targets for improvement
- Consider reflex testing protocols/criteria with the lab and medical director/specialists



https://www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/best-practices/ASB-one-page.pdf https://quality.allianthealth.org/wp-content/uploads/2020/02/UTI-Flyer_12SOW-AHSQIN-QIO-TO1-20-66_508.pdf



Urine Specimen Collection Resource



Urine Specimen COLLECTION

Urine specimen collection is an essential component of urine culture stewardship. Urine culture stewardship is a multifaceted approach to ensure that urine cultures are:

- 1. Performed only when appropriate indications are present to determine if treatment with antibiotics is indicated AND
- 2. Collected, stored and processed in a manner to best prevent contamination with microorganisms such as bacteria.

This approach can be used in patients with and without indwelling urinary catheters in a variety of settings. This resource is intended to support urine specimen collection policies and practices in your facility.



Resident **WITHOUT** Indwelling Urinary Catheters

https://guality.allianthealth.org/wp-content/uploads/2023/08/Urine-Specimen-Collection-Resource_508.pdf



Agency for Healthcare Research and Quality: UTI Diagnosis and Treatment Best Practices

AHRQ Safety Program for Improving Antibiotic Use

Best Practices in the Diagnosis and Treatment of Asymptomatic Bacteriuria and Urinary Tract Infections

PREVENT

HAls

Acute Care



- Explains how to distinguish ASB from a UTI
- Shares the patient populations who should and should not be tested and treated for ASB
- Recommends empiric treatments for UTIs
- Explores opportunities for de-escalation of antibiotic therapy for UTIs after additional clinical data are available
- Examines reasonable durations of antibiotic therapy for UTIs



Thank You for Your Time! Contact the AHS Patient Safety Team <u>patientsafety@allianthealth.org</u>



Amy Ward, MS, BSN, RN, CIC Patient Safety Manager <u>amy.ward@AlliantHealth.org</u> 678.527.3653



Paula St. Hill, MPH, A-IPC Technical Advisor, Infection Prevention paula.sthill@AlliantHealth.org 678.527.3619



Donald Chitanda, MPH, CIC Technical Advisor, Infection Prevention donald.chitanda@allianthealth.org 678.527.3651



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist erica.umeakunne@AlliantHealth.org

quality.allianthealth.org



Making Health Care Better ALABAMA • FLORIDA • GEORGIA • KENTUCKY • LOUISIANA • NORTH CAROLINA • TENNESSEE



This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO-TO1-NH-5200-02/02/24

